ライフサイエンスコーパス: neutralizing antibody

1 els and the efficacy of MEDI-573, an IGF-1/2-neutralizing antibody.

2 s was abrogated in the presence of an irisin-neutralizing antibody.

3 todomain in complex with G4, a stem-directed neutralizing antibody.

4 plex of the HAstV capsid protein and a virus-neutralizing antibody.

5 ce-presented Env, and are targets of broadly neutralizing antibodies.

6 coreceptor binding site and is a target for neutralizing antibodies.

7 ron response and delayed production of virus-neutralizing antibodies.

8 fusion (F) glycoprotein is a key target for neutralizing antibodies.

9 d clonal selection to generate high affinity neutralizing antibodies.

10 ctures of gp120/gp41 or their complexes with neutralizing antibodies.

11 mutants that in turn select affinity-matured neutralizing antibodies.

12 sigma1 protein is also the primary target of neutralizing antibodies.

13 membrane fusion and is the primary target of neutralizing antibodies.

14 fort to identify a vaccine to elicit broadly neutralizing antibodies.

15 ch overlapped with epitope surfaces of known neutralizing antibodies.

16 c Ig produced but not with the production of neutralizing antibodies.

17 nter B cells and eliciting tier-2 autologous neutralizing antibodies.

18 d seemingly opposing results regarding cross-neutralizing antibodies.

19 immune responses that include production of neutralizing antibodies.

20 -H) protein is the main target of protective neutralizing antibodies.

21 It is also the viral component targeted by neutralizing antibodies.

22 ry and is thought to be the major target for neutralizing antibodies.

23 usion (pre-F) state is a superior target for neutralizing antibodies.

24 roducibility with specific detection of ZIKV neutralizing antibodies.

25 -dependent epitopes, which are recognized by neutralizing antibodies.

26 r influence the epitopes of numerous broadly neutralizing antibodies.

27 ly inactivated BNSP333-S1 induced high-titer neutralizing antibodies.

28 on, and the elicitation of tier-2 autologous neutralizing antibodies.

29 d in future clinical trials in patients with neutralizing antibodies.

30 served epitope that is the target of broadly neutralizing antibodies.

31 irus serotypes 1, 2, and 3 targeted by human neutralizing antibodies.

32 e or therapeutic strategies based on broadly neutralizing antibodies.

33 nt cellular cytotoxicity responses and HIV-1-neutralizing antibodies.

34 acaques, but so far failed to induce broadly neutralizing antibodies.

35 ity, such as therapeutic vaccines or broadly neutralizing antibodies.

36 he neutralizing antibodies compared with non-neutralizing antibodies.

37 ocesses controlling the development of HIV-1-neutralizing antibodies.

38 vely resistant to State 1-preferring broadly neutralizing antibodies.

39 on-associated spike, which is the target for neutralizing antibodies.

40 g trimer at 3.2-A resolution in complex with neutralizing antibodies 35O22 and 9H+109L reveals a nati

41 lated a pre-F protein-specific, high-potency neutralizing antibody (5C4) that recognizes antigenic si

42 Previously, we isolated a high-potency neutralizing antibody, 5C4, that specifically recognizes

43 Env is the target of neutralizing antibodies (Abs) and has been the subject o

44 d that cis P-tau elimination with a specific neutralizing antibody administered immediately or at del

45 ry epitope is a target for serotype-specific neutralizing antibodies after DENV3 infection.

46 Similarly, treatment of mice with an IFNAR-neutralizing antibody after MI ablated the interferon re

47 eta-chemokine CCL4, as IFNAR1 deficiency and neutralizing antibodies against CCL4, respectively, abol

48 es.IMPORTANCE One approach to elicit broadly neutralizing antibodies against HIV-1 is to stabilize th

49 inhibitors, bacterial isogenic mutants, and neutralizing antibodies against host proteins recognized

50 e to induce highly potent and broad-spectrum neutralizing antibodies against infection by divergent c

51 mmunogenicity, and they induced strong cross-neutralizing antibodies against infection by divergent p

52 Our data suggest that persons who have neutralizing antibodies against MuV might be protected f

53 ty-determining region loops of human broadly neutralizing antibodies against the hemagglutinin (FI6v3

54 nal center formation and enhanced autologous neutralizing antibodies against the neutralization-resis

55 In our studies, we found that neutralizing antibodies against two New World arenavirus

56 de valuable tools for functionally assessing neutralizing antibodies against vaccine-candidate antige

57 lysis defines reovirus interactions with two neutralizing antibodies, allows us to propose a mechanis

58 ith neutralization titers against 16 broadly neutralizing antibodies and 30 sera from chronic clade C

59 sence of GLA-SE induced high titers of virus-neutralizing antibodies and conferred complete lung prot

60 P1, is an important impediment to binding of neutralizing antibodies and contributes to the poor cros

61 ppress elicitation of V3-directed and tier-1 neutralizing antibodies and induce robust autologous tie

62 The gHgL and gB proteins are targets of neutralizing antibodies and potential candidates for sub

63 ogenic, eliciting complement-independent RSV-neutralizing antibodies and providing protection against

64 apid development of alemtuzumab-binding and -neutralizing antibodies and subsequent occurrence of sec

65 pes on DENV4 E protein targeted by the human neutralizing antibodies and the mechanisms of serotype 4

66 efusion (pre-F) conformation is a target for neutralizing antibodies and therefore an attractive anti

67 elicited increases in antigen binding, virus neutralizing antibody, and T-cell responses.

68 While neutralizing antibodies are highly effective against ebo

69 fective solutions for overcoming preexisting neutralizing antibodies are still lacking.

70 Within this framework, protoxin-neutralizing antibodies are the key effector molecules w

71 /-) mice and those administered a sclerostin-neutralizing antibody are resistant to obesogenic diet-i

72 s interaction with receptor CD4-binding site neutralizing antibodies as a model system, we both corro

73 of time than in serum, and (3) generation of neutralizing antibodies as well as an antiviral immunolo

74 gs are delayed onset and low levels of virus neutralizing antibodies, as well as weak cell-mediated i

75 rred complement-independent high-quality RSV-neutralizing antibodies at titers similar to those of wi

76 protection merits parallel investigation to neutralizing antibody-based vaccine design approaches.

77 AIDS, the search for epitopes recognized by neutralizing antibodies became the driving strategy for

78 angiogenic therapies for cancer such as VEGF neutralizing antibody bevacizumab have limited durabilit

79 defining the immunodominant epitopes and how neutralizing antibodies bind to them will provide great

80 Moreover, TF suppression with neutralizing antibodies blocked 15(S)-HETE-induced monoc

81 recognized by trimer cross-reactive broadly neutralizing antibody (bnAb) and not by nonneutralizing

82 Elicitation of broadly neutralizing antibody (bNAb) responses is a major goal f

83 ability to elicit strong and durable broadly neutralizing antibody (bNAb) responses.

84 VRC01 is an HIV-1 CD4 binding site broadly neutralizing antibody (bnAb) that is active against a br

85 oposes that engineered expression of broadly neutralizing antibodies (bNAbs) against HIV-1 could over

86 are demonstrably less effective than broadly neutralizing antibodies (bNAbs) against HIV-1 in vitro a

87 Broadly neutralizing antibodies (bnAbs) against HIV-1 protect fr

88 Broadly neutralizing antibodies (bNAbs) against human immunodefi

89 covery and characterization of human broadly neutralizing antibodies (bnAbs) against influenza virus

90 Induction of broadly neutralizing antibodies (bnAbs) against this diversity b

91 Broadly neutralizing antibodies (bNAbs) against V1V2 loops, exem

92 In this study, a panel of broadly neutralizing antibodies (bnAbs) and nnAbs, including tho

93 quantify neutralization titers by 16 broadly neutralizing antibodies (bnAbs) and sera from 30 subject

94 protein (Env) is the sole target for broadly neutralizing antibodies (bnAbs) and the focus for design

95 V3-glycan-targeting broadly neutralizing antibodies (bNAbs) are a focus of HIV-1 vac

96 A subset of characterized HIV-1 broadly neutralizing antibodies (bnAbs) are polyreactive with ad

97 rs display the epitopes for multiple broadly neutralizing antibodies (bNAbs) but can also expose bind

98 Induction of broadly neutralizing antibodies (bNAbs) by HIV-1 envelope glycop

99 Such broadly neutralizing antibodies (bnAbs) could in the future beco

100 virus entry and is a major target of broadly neutralizing antibodies (bnAbs) developed during infecti

101 ermline (iGL) forms of several HIV-1 broadly neutralizing antibodies (bNAbs) did not display measurab

102 Broadly neutralizing antibodies (bnAbs) elicited in HIV-1(+) eli

103 Most broadly neutralizing antibodies (BNAbs) elicited in response to

104 erstanding the mechanism(s) by which broadly neutralizing antibodies (bNAbs) emerge naturally followi

105 macaque suggests that elicitation of broadly neutralizing antibodies (bNAbs) for ebolaviruses is poss

106 Broadly neutralizing antibodies (bNAbs) have been evaluated as p

107 Broadly neutralizing antibodies (bNAbs) have been isolated from

108 HIV broadly neutralizing antibodies (bnAbs) have been shown to occas

109 o define envelope (Env) evolution of broadly neutralizing antibodies (bnAbs) in infection and to recr

110 n (Env) immunogen for elicitation of broadly neutralizing antibodies (bNAbs) is a challenging task be

111 Elicitation of broadly neutralizing antibodies (bnAbs) is a primary HIV vaccine

112 are the mainstay for treatment, but broadly neutralizing antibodies (bNAbs) may be a viable alternat

113 lope glycoprotein of HIV-1 and three broadly neutralizing antibodies (bNAbs) of the VRC01 class.

114 ventative HIV vaccine able to elicit broadly neutralizing antibodies (bNAbs) remains a major challeng

115 Majority of the broadly neutralizing antibodies (bnAbs) targeting HIV-1 have bee

116 Induction of HIV-1 broadly neutralizing antibodies (bnAbs) to date has only been ob

117 Broadly neutralizing antibodies (bnAbs) to HIV delineate vaccine

118 Understanding how broadly neutralizing antibodies (bnAbs) to HIV envelope (Env) de

119 a123) increases the ability of human broadly neutralizing antibodies (bNAbs) to inhibit E2-CD81 recep

120 ainst HIV-1 will most likely require broadly neutralizing antibodies (bnAbs) with maximum breadth and

121 iral infectivity and bind to several broadly neutralizing antibodies (bNAbs), including trimer-specif

122 IV-1-infected human subjects develop broadly neutralizing antibodies (bnAbs), such as the potent VRC0

123 Broadly neutralizing antibodies (bNAbs), whilst exhibiting neutr

124 l immunization approach for inducing broadly neutralizing antibodies (bnAbs).

125 candidates aimed at the induction of broadly neutralizing antibodies (bNAbs).

126 f the HIV envelope protein (Env) for broadly neutralizing antibodies (bnAbs).

127 Many HIV-1-infected patients evolve broadly neutralizing antibodies (bnAbs).

128 ity and the difficulty of generating broadly neutralizing antibodies (bnAbs).

129 cation of a new generation of potent broadly neutralizing antibodies (bNAbs).

130 1 primary virus isolates (designated broadly neutralizing antibodies [bNAbs]) remains a high priority

131 ersistence may be linked to the evolution of neutralizing antibody breadth.

132 These data indicate that anti-gHgL neutralizing antibodies can block gHgL-mediated activati

133 as the RV144 vaccine trial indicate that non-neutralizing antibodies can contribute to protection.

134 Finally, administration of G-CSF-neutralizing antibody can prevent the establishment of p

135 ency and magnitude of multiple HIV-1 broadly neutralizing antibody classes are decreased during cell-

136 hat the pre-F state is a superior target for neutralizing antibodies compared to the post-F state.

137 ts of IFN, cellular restriction factors, and neutralizing antibodies compared with cell-free entry.

138 12C trimeric Env preferentially bound to the neutralizing antibodies compared with non-neutralizing a

139 ZIKV-specific neutralizing antibodies correlated with rapid clearance

140 The sustained response of neutralizing antibody correlated temporally with resolut

141 They induced potent neutralizing antibodies cross-neutralizing 17 MERS pseud

142 In the absence of neutralizing antibodies, cross-reactive T cells have bee

143 with tumor necrosis factor alpha (TNF-alpha)-neutralizing antibodies decreased the frequency of CD45(

144 ific CD8 T cell responses and high titers of neutralizing antibodies, demonstrating its superiority t

145 V5E1, ranks as one of the most potent ricin-neutralizing antibodies described to date.

146 rus, to which most of the broadly prevalent, neutralizing antibodies did not bind, conferred a select

147 The induction of neutralizing antibodies directed against the human immun

148 uenza vaccines confer protection by inducing neutralizing antibodies efficiently against homologous a

149 l glycans are components of multiple broadly neutralizing antibody epitopes, while shielding other si

150 Co-culture and neutralizing antibody experiments reveal a cytokine (TNF

151 Neutralizing antibodies fail to provide lasting protecti

152 ogens, have led to the first vaccine-induced neutralizing antibodies for structural and functional an

153 Pretreatment of LAD2 cells with a neutralizing antibody for IL-33 receptor, ST2, inhibits

154 (E1E2) vaccine (genotype 1a) elicited cross-neutralizing antibodies from human volunteers.

155 In this study, with a panel of neutralizing antibodies from three healthy human donors

156 prefusion ectodomain of Lassa GP bound to a neutralizing antibody from a human survivor at 3.2-angst

157 Treatment with an anti-IgE-neutralizing antibody fully reversed vascular inflammati

158 scuss antibody immunodominance pertaining to neutralizing antibody generation and the GC response, pr

159 n the negative effects of immunodominance on neutralizing antibody generation, and consider means of

160 The aptamer competes for binding with the neutralizing antibody H16.V5, indicating at least partia

161 r TNF-alpha gene deletion nor anti-TNF-alpha neutralizing antibodies had any impact sustained eosinop

162 lood and airway after administration of IL-5 neutralizing antibodies has not been reported.

163 Here, we assessed ZIKV-specific neutralizing antibodies in 28 mothers of children with m

164 protect chimpanzees and generate broad cross-neutralizing antibodies in animals and humans.

165 minus in cell-surface binding and a role for neutralizing antibodies in defining structural features

166 erum neutralization to identify and quantify neutralizing antibodies in donor cohorts (Antibodyomics3

167 ene responsible for production of retrovirus-neutralizing antibodies in mice of the I/LnJ strain.

168 rovided by both broadly neutralizing and non-neutralizing antibodies in mice.

169 ll, the RVNT accurately and reliably detects neutralizing antibodies in patient serum specimens, with

170 haracterized epitopes on DENV4 recognized by neutralizing antibodies in people previously exposed to

171 ta clearly indicate the superior efficacy of neutralizing antibodies in preventing mucosal acquisitio

172 derstanding the role of neutralizing and non-neutralizing antibodies in the immune control of HIV inf

173 also positively correlate with the levels of neutralizing antibodies in Zika-virus-infected macaques.

174 Using the structure of a broadly neutralizing antibody in complex with a conserved linear

175 -Ob allele supported the production of virus-neutralizing antibodies independently of the classical M

176 rface glycoprotein and is the main target of neutralizing antibodies induced by natural infection.

177 The development of anti-factor VIII (FVIII) neutralizing antibodies (inhibitors) is the major compli

178 It is among the most potent anti-HIV-1 neutralizing antibodies isolated so far.

179 Most HIV-1-specific neutralizing antibodies isolated to date exhibit unusual

180 tion that the RBS is an important target for neutralizing antibodies, it is not clear how these virus

181 aturation pathway, and prevalence of broadly neutralizing antibody lineages (Antibodyomics1, 2, 4, an

182 in understanding the development of broadly neutralizing antibody lineages (bNAbs).

183 tructure of CVA6 A-particle complexed with a neutralizing antibody maps an immune-dominant neutralizi

184 this action of heparin recapitulates that of neutralizing antibodies, membrane perforation presents a

185 We measured neutralizing antibodies (NAb) against HPV-6, -11, -16, a

186 th hemophilia or blindness, but pre-existing neutralizing antibodies (Nab) are common in the general

187 lates of protection are only poorly defined, neutralizing antibodies (NAb) targeting the envelope pen

188 against congenital HCMV infection.IMPORTANCE Neutralizing antibodies (NAb) targeting the human cytome

189 vaccines are found to induce lower level of neutralizing antibodies (nAb) than do their seasonal cou

190 Understanding whether the neutralizing antibody (NAb) response impacts HIV-1 super

191 Autologous neutralizing antibody (nAb) responses and CD8(+) T-cell

192 Characterizing neutralizing antibody (NAb) responses in individuals inf

193 nantly tier 1 and/or autologous tier 2 virus neutralizing antibody (NAb) responses, as well as weak a

194 is widely accepted that dengue virus (DENV)-neutralizing antibody (nAb) titers are associated with p

195 To assess the value of BKV genotype-specific neutralizing antibody (NAb) titers as a predictive marke

196 Here we use a combination of neutralizing antibody (nAb), mutant mouse and pharmacolo

197 the structural basis for how a mouse-derived neutralizing antibody (nAb), OD01, disrupts this interac

198 Preexisting neutralizing antibodies (NAbs) against adeno-associated

199 c the native Env spike can induce autologous neutralizing antibodies (NAbs) against relatively resist

200 s, with the goal of eliciting broadly active neutralizing antibodies (NAbs) that are active against a

201 these vaccines have generated high titers of neutralizing antibodies (NAbs), their induction of robus

202 native-like trimers expose epitopes for non-neutralizing antibodies (non-nAbs), which may hinder bnA

203 resistant cells to NK cell cytotoxicity when neutralizing antibody of PD-1 or PD-L1 was added.

204 tially favors binding by established broadly neutralizing antibodies; omission of several specific gl

205 (OXA) EoE mice were treated with anti-GM-CSF neutralizing antibody or isotype control and assessed fo

206 Suppressed CCL5/STAT5 signals via CCL5 neutralizing antibody or STAT5 inhibitor Pimozide led to

207 altering neutralization by human CD4-Ig, SIV neutralizing antibodies, or sera from SIV-infected macaq

208 In this study, we show that the broadly neutralizing antibody PGT121, which neutralized only up

209 T cells by the HIV envelope-specific broadly neutralizing antibody PGT121.

210 1 SOSIP.664 gp140, does not bind the broadly neutralizing antibody PGT151 and so was used here to ide

211 Neutralizing antibodies present a possible therapeutic a

212 for the first time that HVEM-specific HSV-1 neutralizing antibodies protect mice from HSV-1 eye dise

213 thod provides critical insights into broadly neutralizing antibody recognition of Env, which may info

214 We apply this approach to PGT151, a broadly neutralizing antibody recognizing a combination of Env r

215 velopment of vaccines able to induce broadly neutralizing antibodies remains the ultimate goal, to da

216 year after HIV infection, a relatively weak neutralizing antibody response against primary and subty

217 The prM-E VLPs induced a strong neutralizing antibody response in mice that was better w

218 y produced a more potent secondary anti-RABV neutralizing antibody response than rLBNSE-immunized mic

219 protein is considered a major target of the neutralizing antibody response to hRSV.

220 ly in the trauma-induced corneas; however, a neutralizing antibody response to the vector capsid was

221 antigenic features required for a protective neutralizing antibody response.

222 issue tropism, and are often targeted by the neutralizing antibody response.

223 primary viruses and recapitulated the serum neutralizing antibody response.

224 new gp120 trimer immunogens elicited potent neutralizing antibody responses against highly sensitive

225 e dose of the rISFV vaccine vectors elicited neutralizing antibody responses and protected mice from

226 The neutralizing antibody responses and the epitopes targete

227 nd 2, plasma immunoglobulin (Ig) G, IgA, and neutralizing antibody responses at week 2 were all signi

228 ction are associated with the development of neutralizing antibody responses following AIM.

229 In stark contrast to SUDV survivors, rare neutralizing antibody responses in MARV survivors dimini

230 2b deletion may allow the parasite to escape neutralizing antibody responses in some regions.

231 P-based vaccines showed significantly better neutralizing antibody responses than those with their DN

232 D8 is also a target for neutralizing antibody responses that are elicited by the

233 We find autoimmune mice generate neutralizing antibody responses to tier 2 HIV-1 strains

234 The highest RSV neutralizing antibody responses were in the 30 microg RS

235 highly sensitive Tier 1A isolates and weaker neutralizing antibody responses with an average titer of

236 In parallel, to characterize the serum neutralizing antibody responses, convalescence-phase ser

237 ity (ADCC), and low-titer tier 1B and tier 2 neutralizing antibody responses.

238 Treatment of animals with an anti-podoplanin neutralizing antibody resulted in development of smaller

239 acid mutations to HIV Envelope (Env) affect neutralizing antibody sensitivity in the context of repl

240 ompared to overlapping early strain-specific neutralizing antibody (ssNAb) responses to the V3/C3 reg

241 Injection of anti-TNF-alpha neutralizing antibodies suppressed behavioral fever, and

242 us FGF2 function in the DMS, by an anti-FGF2 neutralizing antibody, suppressed alcohol consumption an

243 d 2D_M0,12 versus 2D_M0,6; and assessment of neutralizing antibodies, T cells, B cells, and safety.

244 previous studies, we demonstrated that toxin-neutralizing antibodies target four spatially distinct h

245 IV-1 B/C recombinant Env (LT5.J4b12C) to non-neutralizing antibodies targeting CD4-induced Env epitop

246 complex, rhesus macaques can develop broadly neutralizing antibodies targeting multiple immunogenic s

247 Here, we structurally investigated two neutralizing antibodies that bind the attachment protein

248 live attenuated serotype 4 vaccine developed neutralizing antibodies that bound to similar sites on t

249 nsmitted/founder (TF) Env induces autologous neutralizing antibodies that can not only neutralize the

250 The vaccine confers protection by inducing neutralizing antibodies that interfere with the function

251 rapid (within 4 d) and long-lasting (>290 d) neutralizing antibodies that provided complete protectio

252 on the surface of HIV-1 and is the target of neutralizing antibodies that reduce viral infectivity.

253 tural and functional characterization of two neutralizing antibodies that target sigma1 of serotype 1

254 infection and vaccination also induced serum-neutralizing antibodies that targeted similar epitope do

255 lation are not correlated with production of neutralizing antibodies, the levels of which are similar

256 eim Vetmedica) resulted in the production of neutralizing antibodies, the levels of which were signif

257 nduced sterilizing immunity with a saturated neutralizing antibody titer, which no longer increased a

258 Of 47 subjects, 43 (91.5%) subjects had JE neutralizing antibody titers >/=10 (reciprocal serum dil

259 oduced virus-like particles resulted in high neutralizing antibody titers ( approximately 1/100,000)

260 engineered immunogen is able to elicit high neutralizing antibody titers against MERS-CoV.

261 ssive immunity of the offspring, measured by neutralizing antibody titers and survival rates after vi

262 total anti-IAV IgG and IgA titers and virus-neutralizing antibody titers but not hemagglutinin stalk

263 ody cloning shows that donors with high ZIKV neutralizing antibody titers have expanded clones of mem

264 fusion conformation (DS-Cav1 F) induces high neutralizing antibody titers in naive animals, but it re

265 es in mice showed that VLPs generated higher neutralizing antibody titers than those with the DNA vac

266 the prefusion F mutant did not induce higher neutralizing antibody titers than wild-type F.

267 ce occurs despite the presence of high serum neutralizing antibody titers.

268 RNT, nine were negative, eight specimens had neutralizing antibodies to a flavivirus (unable to be id

269 th no preexisting immunity to DENV developed neutralizing antibodies to all 4 serotypes of DENV.

270 nized by some of the most potent and broadly neutralizing antibodies to date.

271 Because neutralizing antibodies to EDE have therapeutic potentia

272 hIVIG, which contained neutralizing antibodies to EV-D68, reduced paralysis in

273 No neutralizing antibodies to evolocumab were detected.

274 No neutralizing antibodies to factor VIII were detected.

275 experimental animals have shown that broadly neutralizing antibodies to HIV-1 can prevent infection,

276 natural immunity, we used a panel of broadly neutralizing antibodies to identify the immunogenic site

277 ficance of the phenomenon for the ability of neutralizing antibodies to mediate protective effects in

278 Postvaccination concentrations of neutralizing antibodies to RV5 were negatively correlate

279 No neutralizing antibodies to the ADC or antibody were dete

280 a vaccine most likely has to induce broadly neutralizing antibodies to the HIV-1 envelope glycoprote

281 Cross-reactive neutralizing antibodies to the RSV and HMPV fusion (F) p

282 masome and fibrosis markers in HSCs and that neutralizing antibody to CCL5 inhibited activation.

283 correlate of protection and the failure of a neutralizing antibody to correlate with protection again

284 3 predominantly blocked the binding of a non-neutralizing antibody to Delta123, while having reduced

285 A blocking peptide, as well as a neutralizing antibody to E-cadherin, works synergistical

286 Administration of FGF2 neutralizing antibody to mice bearing experimental liver

287 No participants tested positive for AAV5-neutralizing antibodies using a green-fluorescent protei

288 The induction of similar cross-reactive neutralizing antibodies using structural vaccinology app

289 ression of CXCL13 resulted in enhanced virus-neutralizing antibody (VNA) production and protection ag

290 with LBNSE-CXCL13 produced more rabies virus-neutralizing antibodies (VNAs) and developed better prot

291 lived PCs, it also generated prolonged virus-neutralizing antibodies (VNAs), resulting in better prot

292 of an HIV-1 strain resistant to the broadly neutralizing antibodies VRC01 and 3BNC117.

293 on of HIV-1 strains resistant to the broadly neutralizing antibodies VRC01 and 3BNC117.

294 Resistance to neutralizing antibodies was dependent on high-level expr

295 In addition, intra-mPFC infusion of a BDNF-neutralizing antibody was performed to test the necessit

296 Neutralizing antibodies were detected in a peripheral bl

297 Anti-MmuPV1 neutralizing antibodies were detected in the sera of all

298 ed that anti-transforming growth factor beta neutralizing antibody, when incubated with conditioned m

299 also leads to the production of tier 2 HIV-1-neutralizing antibodies, which increase in breadth and p

300 er development programs is to induce broadly neutralizing antibodies with the potential to intervene